Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

984724

registered interest
date	10/10/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Dental Services: Coventry
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what estimate he has made of the number of dental practices in Coventry that have availability for NHS patients since 2010.
tabling member constituency	Coventry South
tabling member printed	Mr Jim Cunningham
uin	177592
answer	answer is ministerial correction date of answer 15/10/2018 answer text <p>Data is not held on the number of dental practices in Coventry that had availability to take on new patients since 2010. Practices holding contracts with the National Health Service to deliver primary care dentistry take on new patients as and when they have availability. This data is not held centrally in the format requested.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 15/10/2018 14:31:32 answering member 4067 label Biography information for Steve Brine
tabling member	308 label Biography information for Mr Jim Cunningham

984731

registered interest
date	10/10/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Sepsis: Death
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential effect on the number of sepsis-related deaths in hospital of lifting the restriction on nurses carrying iodine.
tabling member constituency	Croydon Central
tabling member printed	Sarah Jones
uin	177789
answer	answer is ministerial correction date of answer 15/10/2018 answer text <p>The Department has not made an assessment of these issues.</p> answering member constituency Gosport answering member printed Caroline Dinenage grouped question UIN 177790 question first answered 15/10/2018 14:27:45 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	4631 label Biography information for Sarah Jones

984732

registered interest
date	10/10/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Sepsis: Death
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of requiring pharmacists to keep a fixed stock of iodine to help reduce the number of sepsis-related deaths in hospitals.
tabling member constituency	Croydon Central
tabling member printed	Sarah Jones
uin	177790
answer	answer is ministerial correction date of answer 15/10/2018 answer text <p>The Department has not made an assessment of these issues.</p> answering member constituency Gosport answering member printed Caroline Dinenage grouped question UIN 177789 question first answered 15/10/2018 14:27:45 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	4631 label Biography information for Sarah Jones

984790

registered interest
date	10/10/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Fibromyalgia
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will take steps to ensure the maintenance of funding for research into the field of fibromyalgia syndrome and its symptoms.
tabling member constituency	Bath
tabling member printed	Wera Hobhouse
uin	177774
answer	answer is ministerial correction date of answer 15/10/2018 answer text <p>The Department’s National Institute for Health Research (NIHR) welcomes funding applications for research into any aspect of human health, including fibromyalgia; it is not usual practice to ring-fence funds for particular topics or conditions. Applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money and scientific quality. NIHR support for fibromyalgia research over the last five years includes £1.8 million funding for research projects; £0.6 million funding for clinical trials through the NIHR Clinical Research Network; and the NIHR has managed infrastructure supporting fibromyalgia research.</p><p> </p><p>Information on individual projects funded by the NIHR can be found at the following link:</p><p> </p><p><a href="https://www.journalslibrary.nihr.ac.uk/programmes/" target="_blank">https://www.journalslibrary.nihr.ac.uk/programmes/</a></p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 15/10/2018 14:29:28 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	4602 label Biography information for Wera Hobhouse

984795

registered interest
date	10/10/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Fibromyalgia
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if his Department will review the clinical guidelines on the treatment of fibromyalgia syndrome to ensure clearer treatment pathways for people with that syndrome.
tabling member constituency	Bath
tabling member printed	Wera Hobhouse
uin	177775
answer	answer is ministerial correction date of answer 15/10/2018 answer text <p>The Department is not directly responsible for developing or reviewing clinical guidance for identification and management of diseases and disorders. The National Institute for Health and Care Excellence was established by the Government to develop evidence based best practice for the National Health Service. Other organisations, such as the clinical Royal Colleges, and charitable organisations also convene expert groups to develop guidance for health professionals.</p><p> </p><p>A range of support exists to help general practitioners (GPs) identify and manage fibromyalgia in primary care. This includes an e-learning course developed by the Royal College of GPs and Arthritis Research UK on musculoskeletal care, including fibromyalgia, and a medical guide developed by the Fibromyalgia Association UK (FMUK) for health professionals.</p><p> </p><p>People with fibromyalgia can usually be managed through routine access to primary or second care provide via a GP or consultant. Treatment will depend on the severity of a patient’s condition, but may include pain relieving medication; physiotherapy; dietary and exercise advice; counselling or cognitive behavioural therapy. For patients whose pain cannot be adequately controlled by routine access to NHS services, a referral may be made to a specialist pain service or specialist fibromyalgia clinic, such the Royal National Hospital for Rheumatic Diseases in Bath, subject to their having met certain criteria.</p><p> </p><p>Information for the public can be found on the NHS website and is also available in a patient’s information guide produced by FMUK. The medical guide, patient information booklet and NHS choice webpage on fibromyalgia can be found at the following links:</p><p><br> <a href="http://www.fmauk.org/dmdocuments/Medical%20Pack.pdf" target="_blank">www.fmauk.org/dmdocuments/Medical%20Pack.pdf</a></p><p><br> <a href="http://www.fmauk.org/information-packs-mainmenu-58/booklet-mainmenu-135/490-patient-booklet" target="_blank">www.fmauk.org/information-packs-mainmenu-58/booklet-mainmenu-135/490-patient-booklet</a></p><p><br> <a href="http://www.nhs.uk/conditions/fibromyalgia/" target="_blank">www.nhs.uk/conditions/fibromyalgia/</a></p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 177776 question first answered 15/10/2018 14:42:42 answering member 4067 label Biography information for Steve Brine
tabling member	4602 label Biography information for Wera Hobhouse

984889

registered interest
date	10/10/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Influenza: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, which companies supply flu vaccine to (a) his Department and (b) the NHS for (i) people over 65 years of age and (ii) children; and what proportion of those vaccines are supplied by each such company.
tabling member constituency	Garston and Halewood
tabling member printed	Maria Eagle
uin	177604
answer	answer is ministerial correction date of answer 15/10/2018 answer text <p>Public Health England centrally procures flu vaccines for the children’s national flu immunisation programme, these being the nasal spray Fluenz Tetra supplied by AstraZeneca and a quadrivalent inactivated influenza vaccine supplied by Sanofi Pasteur.</p><p> </p><p>Flu vaccines for the adult programme are locally procured directly by providers (e.g. general practitioners and pharmacies). Details of all influenza vaccines available for the 2018/19 season, and the age indications are available in the following table. Seqirus supplies an influenza vaccine which is specifically for those 65 years of age and over (Fluad).</p><p> </p><p>The volume of vaccines supplied by each pharmaceutical company is not available.</p><p> </p><p>Influenza vaccines for the 2018-19 season</p><table><tbody><tr><td><p>Supplier</p></td><td><p>Product details</p></td><td><p>Vaccine type</p></td><td><p>Age indications</p></td></tr><tr><td><p>AstraZeneca UK Ltd</p></td><td><p>Fluenz Tetra</p></td><td><p>Live attenuated, nasal (quadrivalent)</p></td><td><p>From 24 months to less than 18 years of age</p></td></tr><tr><td><p>GSK</p></td><td><p>Fluarix Tetra</p></td><td><p>Split virion inactivated virus (quadrivalent)</p></td><td><p>From six months</p></td></tr><tr><td><p>MASTA</p></td><td><p>Quadrivalent Influenza Vaccine (split virion, inactivated)</p></td><td><p>Split virion, inactivated virus</p></td><td><p>From six months</p></td></tr><tr><td rowspan="2"><p>Mylan (BGP Products)</p></td><td><p>Influvac sub-unit Imuvac Influenza vaccine MYL</p></td><td><p>Surface antigen, inactivated virus</p></td><td><p>From six months</p></td></tr><tr><td><p>Quadrivalent Influenza vaccine Tetra MYL Quadrivalent Influvac sub-unit Tetra</p></td><td><p>Influenza virus surface antigen (inactivated)</p></td><td><p>From 18 years</p></td></tr><tr><td><p>Pfizer Vaccines</p></td><td><p>Influenza vaccine (Split Virion, inactivated), pre-filled syringe</p></td><td><p>Split virion, inactivated virus</p></td><td><p>From five years</p></td></tr><tr><td><p>Sanofi Pasteur vaccines</p></td><td><p>Quadrivalent Influenza Vaccine (split virion, inactivated)</p></td><td><p>Split virion, inactivated virus</p></td><td><p>From six months</p></td></tr><tr><td><p>Seqirus UK Ltd</p></td><td><p>Fluad</p></td><td><p>Surface antigen, inactivated, Adjuvanted with MF59C.1</p></td><td><p>65 years of age and over</p></td></tr></tbody></table><p>Source:</p><p><a href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/744508/VU_286_september_2018.pdf" target="_blank">https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/744508/VU_286_september_2018.pdf</a></p><p> </p><p>Notes:</p><ol><li>The ovalbumin (egg) content is provided in units of micrograms/ml and micrograms/dose.</li><li>None of the influenza vaccines for the 2018-19 season contain thiomersal as an added preservative.</li></ol> answering member constituency Winchester answering member printed Steve Brine question first answered 15/10/2018 14:33:56 answering member 4067 label Biography information for Steve Brine
tabling member	483 label Biography information for Maria Eagle

984890

registered interest
date	10/10/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Influenza: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what information his Department holds on problems with the supply of flu vaccines; and if he will make a statement.
tabling member constituency	Garston and Halewood
tabling member printed	Maria Eagle
uin	177605
answer	answer is ministerial correction date of answer 15/10/2018 answer text <p>NHS England wrote in February 2018 to general practitioner (GPs) and community pharmacists recommending that they should order the adjuvanted trivalent flu vaccine for those aged 65 years and over for the 2018/19 season. This vaccine is intended to offer better protection than the vaccines offered previously to this age group. There is no shortage overall but deliveries of the vaccine will be phased between September and November. The letter is available at the following link:</p><p> </p><p><a href="https://www.england.nhs.uk/wp-content/uploads/2018/02/vaccine-ordering-18-19-influenza-season-gp-pharm.pdf" target="_blank">https://www.england.nhs.uk/wp-content/uploads/2018/02/vaccine-ordering-18-19-influenza-season-gp-pharm.pdf</a></p><p> </p><p>NHS England issued guidance to assist GP practices and community pharmacists to plan their flu clinics in August 2018. Patients are advised to wait for the most appropriate vaccine. The guidance is available at the following links:</p><p> </p><p><a href="https://www.england.nhs.uk/publication/flu-vaccinations-for-2018-and-planning-flu-clinics-letter-from-david-geddes/" target="_blank">https://www.england.nhs.uk/publication/flu-vaccinations-for-2018-and-planning-flu-clinics-letter-from-david-geddes/</a></p><p> </p><p><a href="https://www.england.nhs.uk/publication/flu-vaccination-programme-delivery-guidance-2018-19/" target="_blank">https://www.england.nhs.uk/publication/flu-vaccination-programme-delivery-guidance-2018-19/</a></p> answering member constituency Winchester answering member printed Steve Brine question first answered 15/10/2018 14:39:10 answering member 4067 label Biography information for Steve Brine
tabling member	483 label Biography information for Maria Eagle

984927

registered interest
date	10/10/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Gluten-free Foods: Prescriptions
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will take steps to ensure that gluten-free bread and flour is available to Coeliacs on NHS prescription.
tabling member constituency	Bristol North West
tabling member printed	Darren Jones
uin	177784
answer	answer is ministerial correction date of answer 15/10/2018 answer text <p>The Government proposed changes to the availability of gluten free (GF) foods on National Health Service prescription in its March 2017 public consultation. The majority of consultation respondents agreed with the option to restrict GF prescribing to certain foods. The Government has proposed to restrict to bread and mixes following feedback from the consultation. Evidence submitted to the consultation showed that patients generally found GF mixes easier to use and gave better results for baking GF items such as bread. Prescribing data also showed that mixes were more widely prescribed to patients than flour alone.</p><p> </p><p>This option ensures the best use of NHS resources while maintaining availability of staple GF foods for patients on prescription. Work to implement these changes is underway.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 15/10/2018 14:36:55 answering member 4067 label Biography information for Steve Brine
tabling member	4621 label Biography information for Darren Jones

984933

registered interest
date	10/10/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pancreatic Cancer: Cannabis
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether his Department has made an assessment of the (a) safety and (b) effectiveness of the use medical cannabis oil in the palliative care of pancreatic cancer patients who have a history of strokes.
tabling member constituency	Bristol North West
tabling member printed	Darren Jones
uin	177786
answer	answer is ministerial correction date of answer 15/10/2018 answer text <p>Earlier this year the Chief Medical Adviser to the United Kingdom Government, Professor Dame Sally Davies, conducted a review in which she examined evidence of the medicinal benefit of cannabis based products. She found conclusive evidence of the therapeutic benefit of cannabis based medicinal products for certain medical conditions and reasonable evidence of therapeutic benefit in several other medical conditions. That review did not specifically address the safety and efficacy of cannabis oil in the palliative care of pancreatic cancer patients who have a history of strokes.</p><p> </p><p>As a result of the Chief Medical Adviser’s advice, and that of the Advisory Council on the Misuse of Drugs, the Home Office has laid legislation that means that, subject to Parliament, from 1 November certain cannabis-based products, that meet conditions related to the quality of their manufacture and supply routes, can be prescribed by doctors on the specialist register of the General Medical Council.</p><p> </p><p>The regulations do not limit the types of conditions that can be considered for treatment and specialist doctors will no longer need to seek approval from an expert panel in order for patients to access the medicines. Prescription of unlicensed cannabis-based products for medicinal use will fall within existing legal requirements and National Health Service governance arrangements for ‘special’ medicines.</p><p> </p><p>There are a number of pieces of work in train to support clinicians in making prescribing decisions. The National Institute for Health and Care Excellence will produce clinical guidance by October 2019. In the meantime, NHS England has commissioned the British Paediatric Neurology Association and the Royal College of Physicians to provide interim clinical advice to specialist doctors ahead of the regulations coming into force.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 177787 question first answered 15/10/2018 14:40:33 answering member 4067 label Biography information for Steve Brine
tabling member	4621 label Biography information for Darren Jones

984936

registered interest
date	10/10/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pancreatic Cancer: Cannabis
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether medical cannabis oil will be made available for patients with pancreatic cancer that cannot be treated by other available therapies.
tabling member constituency	Bristol North West
tabling member printed	Darren Jones
uin	177787
answer	answer is ministerial correction date of answer 15/10/2018 answer text <p>Earlier this year the Chief Medical Adviser to the United Kingdom Government, Professor Dame Sally Davies, conducted a review in which she examined evidence of the medicinal benefit of cannabis based products. She found conclusive evidence of the therapeutic benefit of cannabis based medicinal products for certain medical conditions and reasonable evidence of therapeutic benefit in several other medical conditions. That review did not specifically address the safety and efficacy of cannabis oil in the palliative care of pancreatic cancer patients who have a history of strokes.</p><p> </p><p>As a result of the Chief Medical Adviser’s advice, and that of the Advisory Council on the Misuse of Drugs, the Home Office has laid legislation that means that, subject to Parliament, from 1 November certain cannabis-based products, that meet conditions related to the quality of their manufacture and supply routes, can be prescribed by doctors on the specialist register of the General Medical Council.</p><p> </p><p>The regulations do not limit the types of conditions that can be considered for treatment and specialist doctors will no longer need to seek approval from an expert panel in order for patients to access the medicines. Prescription of unlicensed cannabis-based products for medicinal use will fall within existing legal requirements and National Health Service governance arrangements for ‘special’ medicines.</p><p> </p><p>There are a number of pieces of work in train to support clinicians in making prescribing decisions. The National Institute for Health and Care Excellence will produce clinical guidance by October 2019. In the meantime, NHS England has commissioned the British Paediatric Neurology Association and the Royal College of Physicians to provide interim clinical advice to specialist doctors ahead of the regulations coming into force.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 177786 question first answered 15/10/2018 14:40:33 answering member 4067 label Biography information for Steve Brine
tabling member	4621 label Biography information for Darren Jones